

## **NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HEMCHECK SWEDEN AB (PUBL)**

The shareholders of Hemcheck Sweden AB (publ), reg. no. 556811-5272 ("**Hemcheck**" or the "**Company**"), are hereby given notice to attend the Annual General Meeting to be held on Tuesday, 25 April 2023 at 10 a.m. at the Company's premises on Nanna Svartz väg 4 in Solna. The registration to the meeting starts at 09.30 a.m.

### **Exercising voting rights at the Annual General Meeting**

Any shareholder wishing to participate at the Annual General Meeting must:

- (i) be entered in the share register kept by Euroclear Sweden AB as per Monday, 17 April 2023, and
- (ii) have registered their intention to participate in the Annual General Meeting to the Company in accordance with the instructions under the heading "*Notification of personal participation or participation by proxy*", in such time that the notification is received by the Company no later than Wednesday, 19 April 2023.

### **Nominee registered shares**

To be entitled to participate in the Annual General Meeting, a shareholder whose shares are registered in the name of a nominee, must in order to be entitled to exercise its voting rights give notice about its intention to participate in the meeting and temporarily register the shares in its own name in the share register at Euroclear. Such registration must be effected no later than on Wednesday, 19 April 2023 and, thus, the shareholder should provide notice to the nominee thereof in due time before that day. Voting rights registrations requested by a shareholder in such time that the voting rights registration has been effected by the nominee no later than on Wednesday, 19 April 2023, will be considered at the presentation of the share register.

### **Notification of personal participation or participation by proxy**

Shareholders wishing to attend the Annual General Meeting in person or by proxy shall notify the Company no later than Wednesday, 19 April 2023, either:

- (i) through e-mail, [info@hemcheck.com](mailto:info@hemcheck.com), or
- (ii) by post to Hemcheck Sweden AB, Nanna Svartz väg 4, 171 65 Solna, Stockholm, Sweden (mark the envelope "AGM 2023").

The notification shall include name or company name, personal identification number or corporate registration number, address, telephone number as well as, where applicable, the number of assistants (maximum two).

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

Anyone who does not wish to attend in person may exercise their right at the Annual General Meeting by proxy with a written, signed and dated power of attorney. If the power of attorney has been issued by a legal entity, a copy of the registration certificate or equivalent document of authorisation for the legal entity must be attached.

To facilitate access to the Annual General Meeting, powers of attorney, registration certificates and other authorisation documents should be received by the Company at the address Hemcheck Sweden AB, Nanna Svartz väg 4, 171 65 Solna, Stockholm (mark the envelope "AGM 2023") well in advance of the Annual General Meeting and preferably no later than Wednesday, 19 April 2023.

Please note that the notification of participation at the Annual General Meeting shall take place even if a shareholder wishes to exercise its voting rights at the Annual General Meeting by proxy. Submission of power of attorney does not constitute a valid notification to the Annual General Meeting.

A power of attorney form is available on the Company's website, [www.hemcheck.com](http://www.hemcheck.com).

### **Items at the Annual General Meeting**

#### Proposed agenda:

1. Opening of the meeting;
2. Election of chairperson of the meeting;
3. Preparation and approval of the voting register;
4. Approval of the agenda;
5. Election of one or two persons to verify the minutes;
6. Determination of whether meeting has been duly convened;
7. Presentation of the annual report and the auditor's report
8. Resolution regarding;
  - a) Adoption of the financial statement and balance sheet;
  - b) Allocation of the Company's profit or loss in accordance with the adopted balance sheet;
  - c) Discharge from liability for the members of the board of directors and the managing director;
9. Decision on the approval of the acquisition of intellectual property rights from Bio Vitos Medical Limited by resolution on
  - a) Divestment of Hemcheck Management AB;

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

- b) Amendment of the articles of association (Amendment 1);
  - c) Reduction of the share capital;
  - d) Amendment of the articles of association (Amendment 2);
  - e) Directed issue of new shares;
  - f) Distribution of shares in Hemcheck Holding AB (to be formed);
10. Determination of the number of directors of the board and deputy directors of the board and the number of auditors and deputy auditors;
  11. Determination of fees for the board of directors and the auditors;
  12. Election of the members of the board of directors, chairman of the board and any deputy board members;
  13. Election of the auditors and any deputy auditors;
  14. Decision on the nomination committee for the next Annual General Meeting;
  15. Resolution regarding adjustment authorization;
  16. Closing of the meeting.

### **Proposed resolutions by the nomination committee**

The nomination committee consisting of Hjalmar Didrikson (representative of Stockholm Karlstad Invest AB), Mathias Karlsson, Henrik Larsson (representative of Almi Invest Norra Mellansverige AB), och Markus Puusepp (representative of SHL Group AB), as well as Anna Dalgaard (the chairman of the board of directors), proposes the following.

#### 2 Election of chairperson of the meeting

The nomination committee proposes that Attorney Eric Ehrencrona at MAQS Advokatbyrå or, in the event of an impediment, the person appointed by the board of directors instead be elected as the chairperson of the Annual General Meeting.

#### 10 Determination of the number of directors of the board and deputy directors of the board and the number of auditors and deputy auditors

The nomination committee proposes that the board of directors shall consist of four directors with no deputies and that a registered audit firm with no deputy auditor shall be elected.

#### 11 Determination of fees for the board of directors and the auditors

The nomination committee proposes that the fees for the board of directors shall be SEK 142,000 (previously SEK 142,000) for the chairman of the board and SEK 71,000 (previously SEK 71,000) for the other directors and that remuneration to the auditor shall be paid according to separate invoicing.

#### 12 Election of the members of the board, chairman of the board and any deputy board members

The nomination committee proposes that Anna Dalgaard, Karin Dahllöf, Hjalmar Didrikson and Mathias Karlsson are reelected as directors of the board for the time until the end of the next annual general meeting. The nomination committee proposes that Anna Dalgaard is reelected as chairman of the board of directors.

#### 13 Election of the auditors and any deputy auditors

PricewaterhouseCoopers AB has informed that the authorized auditor Jan Nyström intend to retire and in the light thereof will resign as auditor in charge. The nomination committee proposes that BDO Göteborg AB is elected as registered audit firm. BDO Göteborg AB has informed that the approved auditor Filip Laurin will be auditor in charge if the annual general meeting resolves in accordance with the proposal.

#### 14 Decision on the nomination committee for the next Annual General Meeting

The nomination committee has resolved not to propose any updated principles for election of nomination committee but that the principles adopted by the annual general meeting 2020 shall continue to be in force until the general meeting has adopted new principles.

### **Proposed resolutions by the board of directors**

#### 8(b) Resolution regarding the allocation of the Company's profit or loss in accordance with the adopted balance sheet

The board of directors proposes that the loss for the year shall be carried forward.

#### 9 Resolution regarding approval of acquisition of intellectual property from Bio Vitos Medical Limited

Hemcheck has, conditional upon the approval of the general meeting, entered into an agreement with Bio Vitos Medical Limited, reg.no. 12114158 ("**Bio Vitos**") to acquire intellectual property. In the light thereof, the board of directors proposes that the general meeting resolves to approve that Hemcheck acquires intellectual property rights from Bio Vitos as follows (the "**Transaction**").

As previously communicated, if the conditional transaction with Bio Vitos is approved, Hemcheck acquires IP-rights regarding the use of iron succinate for the treatment of patients diagnosed with heart failure with reduced ejection fraction (HFrEF) for China, the USA, Japan and the EU excluding Sweden, Denmark, Norway and Finland (the "**IP-Rights**").

The IP-Rights can provide patent protection for 18 years. The substance is supposed to be registered as a medicine under the name Succifer, starting in Europe and the USA, which Bio Vitos estimates will take over 18 months. It will target a large market, as heart failure is common and a large proportion of these patients have iron deficiency. In Sweden alone, over 200,000 people have symptomatic heart failure and about half of them are estimated to have iron deficiency at the same time. This combination of diagnoses leads to increased severity of symptoms and often leads to hospitalizations. Treatment with regular iron tablets is unsatisfactorily due to insufficient absorption in the intestines or some other unknown factor. To treat iron deficiency in patients with heart failure, iron-containing drugs must currently be injected intravenously at a healthcare facility, which is resource-intensive. Iron deficiency occurs in approximately 15% of the population globally and in approximately 50% of patients with heart failure. The presence of iron deficiency leads to poor energy and impaired heart activity that may require hospitalization whether or not anemia is present. In many respects, the symptoms of iron deficiency are similar to those of heart failure. Iron deficiency has a central role for oxygen supply and utilization of oxygen in the tissue. Iron is also essential for blood formation but also important for the energy process in the tissues such as cell respiration, oxidative phosphorylation, nitric oxide formation and for the energy process in the citric acid cycle. This means that cells with high energy needs, such as skeletal muscles and heart muscles, are particularly susceptible to iron deficiency.

In 2018, a 3-month study evaluated oral iron succinate in patients with heart failure and iron deficiency without anemia. The study was conducted at the research unit in Skellefteå Hospital and was led by Dr. Kurt Boman, professor at Umeå University and Dr. Mona Olofsson. In this study, 20 patients with heart failure and iron deficiency without anemia were recruited and given oral iron succinate twice daily for at least 3 months. The primary aim of this pilot study was to investigate iron uptake saturation and iron stores in these patients. A second aim was to explore iron absorption even after 6 weeks. The study showed marked and significantly improved iron saturation and iron stores in the included patients. The supplement was well tolerated, the patient group experienced some well-known and mild side effects of oral iron therapy. Overall, the results of the study show that oral iron succinate given twice daily can be used to treat iron deficiency in heart failure patients without anemia. This is a significant advantage for patients and for healthcare, as the treatment can be carried out at their home and without the discomfort of intravenous injection. This is the first study to show that oral iron therapy using ferrous succinate, in contrast to other oral iron preparations, can restore iron depots and iron saturation.

Current competing treatments involve the injection of iron, unlike Succifer which is taken orally and with equivalent effect, which thus has several advantages, above all it is many times more expensive to give injections than oral tablets. These competing treatments turn over billions of dollars and the goal is for Succifer to take a large share of that market. As over 25 percent of the world's women also suffer from iron deficiency and today's iron supplements are relatively ineffective and can cause side effects, the Company intends, if possible, to also apply for drug approval for Succifer for improved iron absorption, iron saturation and iron stores in women with iron deficiency, if possible.

The Transaction could be summarized in the following main points:

Hemcheck has as per 7 February 2023 entered into agreement with Bio Vitos to acquire the IP-Rights from Bio Vitos. Addendums have been signed as per 16 and 23 March 2023, respectively, according

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

to which the last day to publish notice to general meeting to approve the transaction was delayed one week and the terms for execution of the Transaction was adapted to the Swedish Companies Act. However, the commercial terms and conditions have not been changed. The original agreement and the addendums are below jointly referred to as the “**Agreement**”.

The Agreement is conditional on that the general meeting of Hemcheck resolves in accordance with this Section 9 on the agenda. The IP-Rights are expected to be taken possession of shortly after the Annual General Meeting in Hemcheck (the “**Closing Date**”).

The purchase price for the IP-Rights amounts to in total SEK 17,000,000 and shall be paid as per the Closing Date through delivering a promissory note with the nominal amount of SEK 17,000,000 (the “**Promissory Note**”) According to the Agreement, Bio Vitos has undertaken to subscribe for 259,654,000 shares in Hemcheck for in total SEK 21,000,000 which corresponds to a subscription price of approximately SEK 0.080877 per share. Payment is intended to made through setoff of the Promissory Note and through payment of SEK 4,000,000 in cash. The quota value of the Hemcheck shares is today SEK 0.09 and in order to make it possible to implement the directed issue of shares under section e) below, the board of directors proposes that the general meeting resolves upon reduction of the share capital through which the quota value of the Company’s shares is reduced to approximately SEK 0.014549.

Further, Bio Vitos shall pay SEK 1,230,000 (plus any VAT) to Hemcheck for the right to implement the transaction.

The Transaction is a so-called reversed acquisition. When acquiring the IP-Rights and after the execution of the directed issue of shares, 259,654,000 new shares in Hemcheck will be issued through which the share capital in Hemcheck will increase with SEK 3,777,670.555888. Through the new issue, Bio Vitos will obtain approximately 88.3 percent of the total number of shares and votes in Hemcheck.

According to the takeover rules for Swedish companies whose stocks are traded on the Nasdaq First North Growth Market, Nordic SME and Spotlight Stock Market trading platforms of the Swedish Stock Market Self-Regulation Committee (the “**Takeover Rules**”), mandatory offer requirement arises when party through the acquisition of shares in Hemcheck achieves a shareholding representing at 30 percent of the voting rights of all shares in Hemcheck. Consequently, as a starting point, a mandatory offer requirement arises because of the new issue of shares under section e) below. However, according to the Takeover Rules, the mandatory offer requirement does no longer exist if the party required to fulfil the requirement, within four weeks of the date on which the mandatory offer requirement was triggered take actions so that the shareholding does not represent 30 percent of the voting rights for all shares in Hemcheck. Bio Vito intends, as soon as the new shares in Hemcheck have been allotted, to immediately (i.e. within four weeks from the point of time when the mandatory offer requirement arose) distribute the new shares to its’ shareholders which result in that the mandatory offer requirement no longer exist. None of the shareholders in Bio Vitos will through the distribution of shares achieve a shareholding representing at least 30 percent of the voting rights of all shares in Hemcheck.

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

If the general meeting approves the Transaction, Hemcheck shall as a preparation of the Transaction, transfer the assets and debts of Hemcheck needed for the continued operation of the business to the Company's wholly owned subsidiary Hemcheck Management AB, reg.no 559426-6974 ("**New Hemcheck**"). For example, Hemcheck's agreements with Nasdaq Stockholm AB, Cision, Euroclear Sweden AB and the majority of the capitalized expenditure for research and development and similar will not be included in the asset transfer. The assets and debts relating to Hemcheck business will be transferred to New Hemcheck to book value and New Hemcheck will pay through issuing a promissory note. Hemcheck will then contribute the debt under promissory note to New Hemcheck as an unconditional shareholders' contribution. Finally, all shares in New Hemcheck will then be contributed as an unconditional shareholder's contribution to another wholly owned subsidiary of the Company to be acquired/formed and named Hemcheck Holding AB ("**Hemcheck Holding**"). Hemcheck Holding will be transformed to a CDS-registered company.

Consequently, Hemcheck's former business will be owned by New Hemcheck and New Hemcheck is intended to, firstly, be divested to an independent buyer with the intention to continuing conducting the business. If an agreement regarding divestment of New Hemcheck, conditional upon the approval of the general meeting, is not entered into not later than two weeks before the Annual General Meeting. New Hemcheck shall secondly be divested to an independent buyer with the mission to divest Hemcheck to an independent buyer wishing to continue conducting the business of Hemcheck at which Hemcheck Holding will be entitled to an additional purchase price. If the board of directors does not find an independent buyer willing to assume the divestment assignment on terms commercially acceptable for the board of directors, New Hemcheck shall thirdly be divested to a company owned by the acting external managing director of Hemcheck with the mission to divest New Hemcheck to an independent buyer wishing to continue conducting the business of Hemcheck at which Hemcheck Holding will be entitled to an additional purchase price. The board of directors intends to prepare a statement regarding the terms for a potential transaction with the acting external managing director so that the general meeting could consider the proposal. The statement will be made available at the Company's website during at least two weeks before the general meeting. All shares in Hemcheck Holding are in accordance with section f) below then proposed to be distributed to the current shareholders in Hemcheck immediately after the directed issue of shares under section e) has been registered by the Swedish Companies Registration Office.

If the general meeting resolves to approve the Transaction, the Company's intangible fixed assets (capitalized expenditure for research and development and similar) may have to be written off which may lead to that a material part of the Company's equity might be lost. The equity will however be restored through the directed issue of shares which is proposed under section e) below.

According to the agreement between Hemcheck and Bio Vitos, the Company shall within 7 working days as from the time the directed issue of shares under section e) below has been registered with the Swedish Companies Registration Office, give notice to an extraordinary general meeting to, among other things, elect new board of directors.

*a) Proposal regarding the divestment of New Hemcheck*

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

The board of directors proposes that the general meeting resolves that the assets and debts of Hemcheck needed for the continued operation of the business are transferred to New Hemcheck and to approve that New Hemcheck is firstly divested to an independent buyer who wishes to continue Hemcheck's operations, secondly, to an independent buyer with the assignment to divest New Hemcheck to an independent buyer who wishes to continue Hemcheck's operations, at which Hemcheck Holding shall be entitled to an additional purchase price and thirdly, to a company owned by the acting external managing director with the assignment to divest New Hemcheck to an independent buyer who wishes to continue Hemcheck's operations, at which Hemcheck Holding shall be entitled to an additional purchase price.

*b) Proposal regarding amendment of the articles of association*

The board of directors proposes that the general meeting resolves to adopt new articles of association in accordance with the following.

The amendments are proposed in light of the Transaction and in order to enable the acquisition of the IP-Rights and the reduction of the share capital proposed under section c).

The amendments are as follows:

**Existing wording**

**3 § Business object**

The object of the company's business is to, directly or indirectly, engage in the design, development and sale of medical devices and related activities.

**4 § Share capital**

The company's share capital shall amount to not less than SEK 1,400,000 and not more than SEK 5,600,000.

**Proposed wording**

**3 § Business object**

The object of the company's business is to, directly or indirectly, engage in the design, development and sale of medical devices and pharmaceutical products and related activities.

**4 § Share capital**

The company's share capital shall amount to not less than SEK 500,000 and not more than SEK 2,000,000.

The board of directors or the person appointed by the board of directors, is authorized to make such minor adjustments to this resolution as may be necessary in connection with registration with the Swedish Companies Registration Office or Euroclear Sweden AB.

*c) Proposal regarding reduction of the share capital*

The board of directors of the Company hereby proposes that the general meeting resolves to reduce the share capital in accordance with the terms set out below:

- The purpose of the reduction is to allocate funds to the nonrestricted equity.
- The Company's share capital shall be reduced with SEK 2,593,025.14.
- The reduction shall be made without withdrawal of shares.



*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

By the reduction of the share capital the quotient value of the Company's shares will be lowered from approximately SEK 0.09 to approximately SEK 0.014548.

The resolution to reduce the Company's share capital in accordance with this proposal can be carried out without authorization from the Swedish Companies Registration Office or public court since the Company will carry out a directed share issue which means that the Company's restricted shareholders' equity nor its share capital will be reduced all in all. The proposal to resolve on the directed share issue is set out in a particular proposal according to section e).

The board of directors' proposal to reduce the share capital is conditional upon that the registration of the reduction of share capital by the Swedish Companies Registration Office is made simultaneously as a share capital increase due to the directed share issue according to section e) that corresponds to at least the reduction of share capital.

The board of directors or a person appointed by the board of directors are authorized to carry out minor adjustment to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office or Euroclear Sweden AB.

*d) Proposal regarding amendment of the articles of association*

The board of directors proposes that the general meeting resolves to adopt new articles of association in accordance with the following.

The amendments are proposed in order to enable the directed issue of shares under section e).

The amendments are as follows:

<b>Wording after the amendment in section b) above</b>	<b>Proposed wording</b>
<b>4 § Share capital</b> The company's share capital shall amount to not less than SEK 500,000 and not more than SEK 2,000,000.	<b>4 § Share capital</b> The company's share capital shall amount to not less than SEK 4,000,000 and not more than SEK 16,000,000.
<b>5 § Number of shares</b> The number of shares shall be not less than 15,700,000 and not more than 62,800,000.	<b>5 § Number of shares</b> The number of shares shall be not less than 290,000,000 and not more than 1,160,000,000.

The board of directors or a person appointed by the board of directors are authorized to carry out minor adjustment to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office or Euroclear Sweden AB.

*e) Proposal for a resolution on directed new issue of shares*

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

The board of directors proposes that the general meeting resolves to increase the Company's share capital by SEK 3,777,670.555888 through a new issue of 259,654,000 shares on the following terms:

With deviation from the shareholders' preferential rights, the right to subscribe for the shares shall only belong to Bio Vitos.

The reason for the deviation from the shareholders' preferential rights is that the board of directors deems it advantageous for Hemcheck to enable the execution of the Transaction, which the board of directors in all considers as a measure which is to the benefit of the Company as well as its shareholders since it secures the Company's financial need on short term and gives the Company realistic possibilities to continue generate value for its shareholders. This in combination with the possibility for the Company's current shareholders to also take part of the value that a potential divestment of New Hemcheck would imply indicates, in the board of directors' opinion, with sufficient strength to carry out the directed issue of new shares without preferential rights for the shareholders. The board of directors in this context wants to point out that it has considered a number of alternative potential solutions on the current situation and after thorough considerations come to the conclusion that now suggested measure including the Transaction and the directed issue of shares objectively at the present situation is the best alternative for the Company and its shareholders.

SEK 21,000,000 shall be paid for all 259,654,000 shares, which means that approximately SEK 0.080877 shall be paid for each new share. The part of the subscription rate that exceeds the quotient value shall be added to the free share premium reserve.

The board of directors considers the subscription rate to be on market terms based on a negotiation with Bio Vitos regarding Hemcheck's value after the transfer of the business to New Hemcheck, the transfer of New Hemcheck to Hemcheck Holding, the divestment of New Hemcheck to an independent third party and the distribution of the shares in Hemcheck Holding to the shareholders before the issue is registered with the Swedish Companies Registration Office.

Over-subscription is not possible.

Subscribers may not subscribe for fewer shares than they are entitled to subscribe for.

Subscription of shares shall be made on a separate subscription list no later than 30 June 2023. Payment for subscribed shares shall be made no later than the same day. The board of directors shall be entitled to extend the final date for subscription and payment.

It is noted that the board of directors is entitled to authorize offset in accordance with Chapter 13, Section 41 of the Swedish Companies Act. In the event of payment for the new shares through offset, the offset is made through the share subscription.

The new issue require that the articles of association is amended.

The new shares shall entitle to dividends from the financial year following the year in which the new shares were registered with the Swedish Companies Registration Office. It is noted that this means that the new shares will not entitle to the dividend proposed under section f).

The board of directors or a person appointed by the board of directors are authorized to carry out minor adjustment to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office or Euroclear Sweden AB.

*f) Proposal regarding distribution of shares in Hemcheck Holding*

As mentioned above, in preparation for the Transaction, the assets and debts of Hemcheck needed for the continued operations of the business are intended to be transferred to New Hemcheck. Furthermore, New Hemcheck is intended to be transferred to Hemcheck Holding which in turn is intended to divest New Hemcheck. Given this background, the board of directors proposes that the general meeting resolves on a dividend to the shareholders of Hemcheck consisting of all of Hemcheck's shares in Hemcheck Holding.

The dividend means that the shareholders are entitled to receive one (1) share in Hemcheck Holding for each share they hold as per the record date (*Sw. avstämningsdagen*) in Hemcheck.

The value of the distribution of the shares in Hemcheck Holding is determined on the basis of the book value at the time of the distribution of the shares to Hemcheck's shareholders by applying applicable accounting rules. The board's proposal for distribution corresponds to a total amount of approximately SEK 3.0 million, which corresponds to the book value at the time of this proposal, which is also expected to be the approximate book value of the shares at the time of the distribution of the shares.

As of December 31, 2022, Hemcheck's nonrestricted equity amounted to approximately SEK 4.2 million. According to the annual report for the financial year 2022 proposed to be adopted under section 8a), no dividend is proposed. Provided that no dividend is paid under section 8b), there is thus room in the available amount for the forthcoming dividend proposal.

The distribution of the shares in New Hemcheck is considered to be a so-called Lex ASEA distribution, which means that the distribution does not constitute any immediate taxation for Swedish taxpayers.

The board of directors proposes that the general meeting;

- decides to distribute all shares in Hemcheck Holding to the owners whereby the owners for each share in Hemcheck receive one share in Hemcheck Holding at a value of approximately SEK 0.087293,
- authorize the board of directors to determine the record date for the right to receive shares in Hemcheck Holding, provided that the record date shall occur before 31 December 2023. The board of directors intends to execute the distribution of the shares immediately after the direct issue of shares under section e) above has been registered with the Swedish Companies Registration Office, as well as
- resolves that payment of the dividend shall be made by delivery of shares in Hemcheck Holding to a securities account with Euroclear as soon as possible after the record date.

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

The board of directors or the person appointed by the board of directors, is authorized to make such minor adjustments to this resolution as may be necessary in connection with registration with the Swedish Companies Registration Office or Euroclear Sweden AB.

#### Preparation

The proposal under this section 9 has been prepared by the board of directors of the Company and the acting external managing director has not and will not be involved in the handling of the proposal under section a) regarding the divestment of New Hemcheck.

#### *Majority requirements*

The proposals for resolutions under this section 9 are a combined proposal. For a valid resolution in accordance with the proposal, the resolution must be supported by at least two thirds of as well the votes cast as well as the shares represented at the general meeting.

In addition thereto, the proposal under section a) must in order to be considered approved by the general meeting, have been supported by more than half of the votes cast. At resolution by the general meeting, shares held by the acting external managing director shall not be considered.

#### 15 Resolution regarding adjustment authorization

The board of directors, the acting external managing director or the person appointed by the board of directors shall be authorized to make such minor amendments of the resolution by the Annual General Meeting that may prove necessary in connection with registration of the resolutions.

#### **Number of shares and votes**

At the time of this notice, the total number of shares and votes in the Company amounts to 34,366,946. The Company holds no treasury shares.

#### **Other**

Power of attorney form as well as the annual report and the auditor's report will be made available no later than three weeks before the Annual General Meeting. Complete proposals for resolutions with adhering documents will be made available no later than two weeks prior to the Annual General Meeting. The notice and documents as above will be made available at the Company on Nanna Svartz väg 4, 171 65 Solna, Stockholm and on the Company's website [www.hemcheck.com](http://www.hemcheck.com) and will be sent to shareholders who request it and provide their e-mail or postal address. The Annual General Meeting's shareholder's register is available at the Company's office at the above address.

The shareholders are reminded of the right to, at the Annual General Meeting, request information from the board of directors and the managing director in accordance with Chapter 7, Section 32 of the Swedish Companies Act.

#### **Processing of personal data**

*The English version is a translation of the Swedish original. In the event of any discrepancy between the English and the Swedish version, the Swedish shall prevail.*

For information on how your personal data is processed please see  
<https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf>.

---

Karlstad in March 2023

**Hemcheck Sweden AB**

*The Board of Directors*